OBJECTIVE: To analyse serum concentrations of brain specific S100 protein in patients with Creutzfeldt-Jakob disease and in controls. DESIGN: Prospective case-control study. SETTING: National Creutzfeldt-Jakob disease surveillance unit. SUBJECTS: 224 patients referred to the surveillance unit with suspected Creutzfeldt-Jakob disease and 35 control patients without dementia. MAIN OUTCOME MEASURE: Serum concentration of S100 protein in patients with Creutzfeldt-Jakob disease, in patients with other diseases causing dementia, and in the control group. RESULTS: Of the 224 patients with suspected Creutzfeldt-Jakob disease, 65 were classed as definitely having the disease after neuropathological verification, an additional 6 were classed as definitely having the disease as a result of a genetic mutation, 43 as probably having the disease, 36 as possibly having the disease, and 74 patients were classed as having other disease. In the 108 patients classed as definitely or probably having Creutzfeldt-Jakob disease the median serum concentration of S100 was 395 pg/ml (SD 387 pg/ml). This was significantly higher than concentrations found in the 74 patients classed as having other diseases (median 109 pg/ml; SD 177 pg/ml; P = 0.0001). At a cut off point of 213 pg/ml sensitivity for the diagnosis of the disease was 77.8% (95% confidence interval 68.8% to 85.2%) and specificity was 81.1% (70.3% to 89.3%). There was a significant difference in survival at different concentrations of S100 in Kaplan-Meier curves (P = 0.023). CONCLUSION: Measurement of serum concentrations of S100 is a valuable tool which can be used more easily than tests on cerebrospinal fluid in the differential diagnosis of Creutzfeldt-Jakob disease. More studies are needed to determine whether serial testing of serum S100 improves diagnostic accuracy.
OBJECTIVE: To analyse serum concentrations of brain specific S100 protein in patients with Creutzfeldt-Jakob disease and in controls. DESIGN: Prospective case-control study. SETTING: National Creutzfeldt-Jakob disease surveillance unit. SUBJECTS: 224 patients referred to the surveillance unit with suspected Creutzfeldt-Jakob disease and 35 control patients without dementia. MAIN OUTCOME MEASURE: Serum concentration of S100 protein in patients with Creutzfeldt-Jakob disease, in patients with other diseases causing dementia, and in the control group. RESULTS: Of the 224 patients with suspected Creutzfeldt-Jakob disease, 65 were classed as definitely having the disease after neuropathological verification, an additional 6 were classed as definitely having the disease as a result of a genetic mutation, 43 as probably having the disease, 36 as possibly having the disease, and 74 patients were classed as having other disease. In the 108 patients classed as definitely or probably having Creutzfeldt-Jakob disease the median serum concentration of S100 was 395 pg/ml (SD 387 pg/ml). This was significantly higher than concentrations found in the 74 patients classed as having other diseases (median 109 pg/ml; SD 177 pg/ml; P = 0.0001). At a cut off point of 213 pg/ml sensitivity for the diagnosis of the disease was 77.8% (95% confidence interval 68.8% to 85.2%) and specificity was 81.1% (70.3% to 89.3%). There was a significant difference in survival at different concentrations of S100 in Kaplan-Meier curves (P = 0.023). CONCLUSION: Measurement of serum concentrations of S100 is a valuable tool which can be used more easily than tests on cerebrospinal fluid in the differential diagnosis of Creutzfeldt-Jakob disease. More studies are needed to determine whether serial testing of serum S100 improves diagnostic accuracy.
Authors: M Otto; J Wiltfang; H Tumani; I Zerr; M Lantsch; J Kornhuber; T Weber; H A Kretzschmar; S Poser Journal: Neurosci Lett Date: 1997-04-11 Impact factor: 3.046
Authors: M Otto; H Stein; A Szudra; I Zerr; M Bodemer; O Gefeller; S Poser; H A Kretzschmar; M Mäder; T Weber Journal: J Neurol Date: 1997-09 Impact factor: 4.849
Authors: L Persson; H G Hårdemark; J Gustafsson; G Rundström; I Mendel-Hartvig; T Esscher; S Påhlman Journal: Stroke Date: 1987 Sep-Oct Impact factor: 7.914
Authors: T Jimi; Y Wakayama; S Shibuya; H Nakata; T Tomaru; Y Takahashi; K Kosaka; T Asano; K Kato Journal: Clin Chim Acta Date: 1992-10-15 Impact factor: 3.786
Authors: J Wiltfang; W Nolte; M Otto; J Wildberg; E Bahn; H R Figulla; L Pralle; H Hartmann; E Rüther; G Ramadori Journal: Metab Brain Dis Date: 1999-12 Impact factor: 3.584
Authors: Philipp Spitzer; Hans Wolfgang Klafki; Kaj Blennow; Luc Buée; Hermann Esselmann; Sanna-Kaisa Herruka; Connie Jimenez; Peter Klivenyi; Piotr Lewczuk; Juan Manuel Maler; Katrin Markus; Helmut E Meyer; Chris Morris; Thorsten Müller; Markus Otto; Lucilla Parnetti; Hilkka Soininen; Susanna Schraen; Charlotte Teunissen; Laszlo Vecsei; Henrik Zetterberg; Jens Wiltfang Journal: Int J Alzheimers Dis Date: 2010-09-19
Authors: Wei Xiang; Otto Windl; Gerda Wünsch; Martin Dugas; Alexander Kohlmann; Nicola Dierkes; Ingo M Westner; Hans A Kretzschmar Journal: J Virol Date: 2004-10 Impact factor: 5.103
Authors: Daniel-Paolo Streitbürger; Katrin Arelin; Jürgen Kratzsch; Joachim Thiery; Johann Steiner; Arno Villringer; Karsten Mueller; Matthias L Schroeter Journal: PLoS One Date: 2012-08-14 Impact factor: 3.240